Filing Flows › Atara Biotherapeutics (ATRA) › Q4 2024
Atara Biotherapeutics (ATRA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 7, 2025
Atara Biotherapeutics (ATRA) reported revenue of $32.8M for the fourth quarter 2024 (Q4 2024), +670% from a year earlier and -19% from the quarter before. Operating margin was -37.3%, net loss $12.7M (38.8% of revenue).
Atara Biotherapeutics, Q4 2024: revenue $32.8M (+670% year over year), operating margin -37.3%, net loss $12.7M, operating cash flow −$24.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.8M | -19% | +670% |
| Operating profit | −$12.2M | — | — |
| Net earnings | −$12.7M | — | — |
| Operating cash flow | −$24.5M | — | — |
What changed
Revenue was $32.8M in Q4 2024, up 670% year over year and down 19% from the previous quarter.
Operating costs exceeded revenue by $12.2M, an operating margin of -37.3%. Total costs fell 30% while revenue rose 670%. The fastest-growing cost line was Other operating costs (+115%). The quarter ended with a net loss of $12.7M, narrower than the previous quarter's $21.9M loss.
Operating cash flow was −$24.5M. Non-cash charges added back $1.1M of depreciation and amortization and $5.8M of share-based compensation. Working capital and other items used $18.7M. Capital expenditures of $90K exceeded it, leaving free cash flow of −$24.6M.
Questions
What was Atara Biotherapeutics' revenue in the fourth quarter 2024?
Atara Biotherapeutics (ATRA) reported revenue of $32.8M for the fourth quarter 2024 (Q4 2024), +670% from a year earlier and -19% from the quarter before.
Was Atara Biotherapeutics profitable in the fourth quarter 2024?
Operating loss was $12.2M (-37.3% of revenue) and net loss $12.7M.